Insider Sale: Collegium Pharmaceutical, Inc. (NASDAQ: COLL) CFO Sells 4,350 Shares

Collegium Pharmaceutical, Inc. (NASDAQ: COLL – Get a rating) CFO Colleen Tupper sold 4,350 shares of Collegium Pharmaceutical in a trade that took place on Tuesday, October 4. The stock was sold at an average price of $17.35, for a total transaction of $75,472.50. Following the completion of the transaction, the CFO now owns 90,304 shares of the company, valued at approximately $1,566,774.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink.

Performance of Collegium Pharmaceutical shares

Shares of Collegium Pharmaceutical traded down $0.15 in Thursday’s session, hitting $16.85. The company’s shares had a trading volume of 143,739 shares, compared to an average volume of 322,668. The company has a 50-day moving average price of $17.61 and a two-hundred-day moving average price of 17, $38. Collegium Pharmaceutical, Inc. has a fifty-two-week low of $14.04 and a fifty-two-week high of $22.89. The company has a market capitalization of $575.02 million, a PE ratio of -16.35, a P/E/G ratio of 0.21 and a beta of 0.87. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt ratio of 3.16.

Collegium Pharmaceutical (NASDAQ: COLL- Get a rating) last announced its results on Thursday, August 4. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $1.15 per ($1.19). Collegium Pharmaceutical had a negative return on equity of 2.12% and a negative net margin of 11.24%. The company posted revenue of $123.55 million for the quarter, versus analyst estimates of $122.63 million. On average, analysts expect Collegium Pharmaceutical, Inc. to post EPS of 4.21 for the current year.

Hedge funds weigh on Collegium Pharmaceutical

A number of large investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 22.6% in the second quarter. Principal Financial Group Inc. now owns 1,738,291 shares of the specialty pharmaceutical company valued at $30,802,000 after purchasing an additional 320,778 shares during the period. MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter with a value of $5,660,000. Emerald Advisers LLC increased its stake in Collegium Pharmaceutical by 39.2% during the first quarter. Emerald Advisers LLC now owns 800,118 shares of the specialty pharmaceutical company worth $16,290,000 after purchasing an additional 225,281 shares last quarter. Royce & Associates LP increased its position in Collegium Pharmaceutical by 58.0% during the second quarter. Royce & Associates LP now owns 460,243 shares of the specialty pharmaceutical company worth $8,156,000 after purchasing an additional 168,989 shares during the period. Finally, State Street Corp increased its stake in Collegium Pharmaceutical by 14.4% in the first quarter. State Street Corp now owns 1,308,167 shares of the specialty pharmaceutical company valued at $26,634,000 after buying an additional 165,144 shares last quarter.

Analyst upgrades and downgrades

Separately, HC Wainwright downgraded Collegium Pharmaceutical to a “neutral” rating in a Monday, August 15 report. Two analysts rated the stock with a hold rating and three gave the company a buy rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.25.

About Collegium Pharmaceutical

(Get a rating)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets drugs for pain management. Its portfolio includes Xtampza ER, an oral, extended-release, abuse-deterrent oxycodone formulation; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid therapy.

Featured articles

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Collegium Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Collegium Pharmaceutical didn’t make the list.

While Collegium Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here